Articles published by Arrowhead Pharmaceuticals, Inc.
![](https://mms.businesswire.com/media/20240821261066/en/523535/5/ah_logo_cmyk.jpg)
![](https://mms.businesswire.com/media/20240814618768/en/523535/5/ah_logo_cmyk.jpg)
![](https://mms.businesswire.com/media/20240808386450/en/523535/5/ah_logo_cmyk.jpg)
Via Business Wire
Tickers
ARWR
![](https://mms.businesswire.com/media/20240808218819/en/523535/5/ah_logo_cmyk.jpg)
Arrowhead Pharmaceuticals Announces $500 Million Strategic Financing Facility with Sixth Street
August 08, 2024
Via Business Wire
Tickers
ARWR
![](https://mms.businesswire.com/media/20240729420204/en/523535/5/ah_logo_cmyk.jpg)
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
July 29, 2024
Via Business Wire
Tickers
ARWR
![](https://mms.businesswire.com/media/20240724228514/en/523535/5/ah_logo_cmyk.jpg)
Via Business Wire
Tickers
ARWR
![](https://mms.businesswire.com/media/20240625867892/en/523535/5/ah_logo_cmyk.jpg)
![](https://mms.businesswire.com/media/20240624437222/en/523535/5/ah_logo_cmyk.jpg)
![](https://mms.businesswire.com/media/20240603389820/en/523535/5/ah_logo_cmyk.jpg)
![](https://mms.businesswire.com/media/20240531115413/en/523535/5/ah_logo_cmyk.jpg)
Via Business Wire
Tickers
ARWR
![](https://mms.businesswire.com/media/20240529131669/en/523535/5/ah_logo_cmyk.jpg)
![](https://mms.businesswire.com/media/20240528218677/en/523535/5/ah_logo_cmyk.jpg)
![](https://mms.businesswire.com/media/20240520575548/en/523535/5/ah_logo_cmyk.jpg)
![](https://mms.businesswire.com/media/20240509969239/en/523535/5/ah_logo_cmyk.jpg)
Via Business Wire
Tickers
ARWR
![](https://mms.businesswire.com/media/20240502387280/en/523535/5/ah_logo_cmyk.jpg)
Via Business Wire
Tickers
ARWR
![](https://mms.businesswire.com/media/20240429808194/en/523535/5/ah_logo_cmyk.jpg)
Via Business Wire
Tickers
ARWR
![](https://mms.businesswire.com/media/20240426688911/en/523535/5/ah_logo_cmyk.jpg)
Via Business Wire
Tickers
ARWR
![](https://mms.businesswire.com/media/20240424061915/en/523535/5/ah_logo_cmyk.jpg)
Via Business Wire
Tickers
ARWR
![](https://mms.businesswire.com/media/20240424663343/en/523535/5/ah_logo_cmyk.jpg)
![](https://mms.businesswire.com/media/20240407461180/en/523535/5/ah_logo_cmyk.jpg)
![](https://mms.businesswire.com/media/20240401204452/en/523535/5/ah_logo_cmyk.jpg)
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
April 01, 2024
Via Business Wire
Tickers
ARWR
![](https://mms.businesswire.com/media/20240325486042/en/523535/5/ah_logo_cmyk.jpg)
![](https://mms.businesswire.com/media/20240308355853/en/523535/5/ah_logo_cmyk.jpg)
![](https://mms.businesswire.com/media/20240304461027/en/523535/5/ah_logo_cmyk.jpg)
Via Business Wire
Tickers
ARWR
![](https://mms.businesswire.com/media/20240206347296/en/523535/5/ah_logo_cmyk.jpg)
Arrowhead Pharmaceuticals Reports Fiscal 2024 First Quarter Results
February 06, 2024
Via Business Wire
Tickers
ARWR
![](https://mms.businesswire.com/media/20240122268016/en/523535/5/ah_logo_cmyk.jpg)
Via Business Wire
Tickers
ARWR
![](https://mms.businesswire.com/media/20240105913237/en/523535/5/ah_logo_cmyk.jpg)
Arrowhead Pharmaceuticals Closes Underwritten Offering with Gross Proceeds of $450.0 Million
January 05, 2024
Via Business Wire
Tickers
ARWR
![](https://mms.businesswire.com/media/20240103088469/en/523535/5/ah_logo_cmyk.jpg)
Arrowhead Pharmaceuticals Announces Pricing of $450.0 Million Underwritten Offering of Common Stock
January 03, 2024
Via Business Wire
Tickers
ARWR
![](https://mms.businesswire.com/media/20231229398285/en/523535/5/ah_logo_cmyk.jpg)
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
December 29, 2023
Via Business Wire
Tickers
ARWR
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.